BLINATUMOMAB
blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL
vial], 1 pack
BLINATUMOMAB (11117D)
11117D
Manner of administration:Injection
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Consolidation treatment of relapsed or refractory B-precursor cell ALL
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 784 mcg | # of repeats: 2 | DPMA: $77,358.07 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Blincyto
(blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL
vial], 1 pack)
|
||||